Assessment of disability (EDSS) and liver complications in multiple sclerosis patients treated by Recigen in comparison with Betaferon.

Multiple sclerosis (MS) is a chronic neurologic disease. At the present time، Rebif، which is the most effective drug in treatment of MS after Avonex، is used to prevent relapses. Recigen is Iranian generation of Rebif. It is almost a year since the entry of Recigen into our pharmaceutical market and it is virtually superseding American Rebif، but no study has been performed on efficacy and hepatic side effects of this drug. The aim of this study is to compare the efficacy and side effects of Betafron and Recigen in medical university of mashhad in 1389-1390. This was a single blind study conducted in neurology department of Qaem hospital on MS patients who fulfil criretia for pharmacotherapy indications. EDSS، complications and symptoms were compared in Betafron and Recigen group. Demographic data were analyzed using SPSS software. Demographic characteristics (like age and sex) were similar in both groups with no significant differences. There were no significant differences in EDSS and hepatic side effects in both Betafron and Recigen groups (p=0. 134). Relapse rate was significantly lower in Betafron group (p=0. 03). It seems both drugs has the same rate of side effects and EDSS scores. Recigen has similar efficacy in comparison with Betafron، though it cannot prevent relapses in short time.